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Bisphosphonates prevent 
experimental vascular 
calcification: Treat the bone to 
cure the vessels?
V Persy1, M De Broe1 and M Ketteler2
Bisphosphonates are inhibitors of bone resorption that are widely 
used to treat osteoporosis. Price and colleagues demonstrate that 
ibandronate suppressed the development of uremia-related vascular 
calcification in rats. These findings extend the link between bone 
remodeling and vascular calcification to the context of chronic renal 
failure, opening perspectives toward novel therapeutic strategies.
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Chronic kidney disease is associated with 
a strong increase in cardiovascular risk, 
which is responsible for approximately 
50% of the mortality in the hemodial-
ysis population. Increased vascular 
calcification is a prominent feature of 
vascular disease in uremic patients. 
Coronary calcifi cation is already present 
in young hemodialysis patients and 
shows rapid progression. In addition to 
increased calcifi cation of atherosclerotic 
plaques, patients on dialysis also show 
characteristic calcifi cations of the vascu-
lar tunica media, which also contribute 
signifi cantly to the excess cardiovascular 
mortality observed in uremic patients.1
Price et al.2 (this issue) report that the 
bisphosphonate ibandronate prevents the 
development of vascular calcifi cation in 
rats with adenine-induced chronic renal 
failure maintained on a low-protein diet.
Combination of adenine-induced 
chronic renal failure with a synthetic 
diet with low protein content proved to 
reliably induce media calcifi cation in the 
large arteries of these animals, whereas 
the standard model induces vascular 
calcifi cation only in a subset of animals3 
(V Persy et al., unpublished observations). 
The availability of a reliable model of 
uremia-induced vascular calcifi cation is 
an important asset for future experimen-
tal research into the pathomechanisms 
of pharmacological agents and their 
impact on artery calcifi cation in chronic 
renal failure. Moreover, this fi nding is 
not without its implications for human 
disease: dietary protein restriction is still 
occasionally used in chronic kidney dis-
ease patients in order to slow progression 
of kidney-function deterioration and is 
one of the standard measures imposed on 
dialysis patients to keep phosphate levels 
under control; malnutrition always looms 
around the corner for these patients. So 
maintaining a good nutritional status in 
end-stage renal failure patients is impor-
tant not only to fi ght off  chronic infl am-
mation, but possibly also to limit the 
development of vascular calcifi cation.
Bisphosphonates are pyrophosphate 
analogues resistant to enzymatic hydro-
lysis that are widely used to treat bone 
diseases characterized by increased bone 
resorption, such as osteoporosis, Paget’s 
disease, osteolytic lesions, and hypercal-
cemia associated with multiple myeloma. 
In high doses these compounds physi-
cochemically inhibit mineralization by 
inhibiting the formation and aggregation 
of calcium phosphate crystals and block-
ing the transformation of amorphous 
calcium phosphate to hydroxyapatite. 
However, their therapeutic use depends on 
their inhibition of bone resorption, which 
occurs at low doses that do not aff ect min-
eralization.4 Bisphosphonates increase 
the bone mineral density of osteoporotic 
patients by inhibiting osteoclastic bone 
resorption through several mechanisms: 
they inhibit terminal diff erentiation of 
osteoclasts, induce apoptosis of osteo-
clasts, and decrease osteoclastic activity 
by inhibiting protein prenylation.4
However, bisphosphonates are also 
reported to act on cells of the osteo-
blastic lineage,5 and the eff ect of diff erent 
bisphosphonate compounds on osteo-
blastic cells correlates well with their dif-
ferent potency in vivo.4
The findings reported in this issue2 
extend results previously reported by 
Price’s group showing that bisphospho-
nates can inhibit the development of 
arterial calcifi cation in rats with normal 
renal function treated with warfarin or 
toxic doses of vitamin D,6 and they add 
to the growing body of experimental evi-
dence that links vascular calcifi cation to 
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metabolic bone disease. This study2 
represents the first experimental evi-
dence implicating bone resorption in 
the pathogenesis of uremia-related 
vascular calcifi cation. Recently, the less 
potent bisphosphonate etidronate was 
also reported to prevent aortic calcifi ca-
tion in fi ve-sixths nephrectomized rats 
treated with calcitriol to induce vascular 
calcifi cation.7 However, Tamura et al.7 
used a high dose of etidronate (10 mg/
kg), which also inhibits mineralization. A 
few clinical studies in which bisphospho-
nates were administered to small num-
bers of hemodialysis patients generated 
hopeful results for the potential use of 
these compounds to fi ght uremia-related 
arterial calcifi cation: Nitta et al.8 demon-
strated that etidronate treatment arrested 
progression of coronary calcification, 
whereas Hashiba and colleagues9 found 
no increase in aorta calcifi cation over a 
23-month follow-up period in patients 
treated with the same compound, con-
trasting with significant progression 
of calcifi cation in the control group. In 
addition, two recent case reports docu-
mented the potential usefulness of etid-
ronate and pamidronate, respectively, as 
treatment options in calciphylaxis.10,11
Outside the uremic setting, the phe-
notype of the osteoprotegerin knockout 
mouse also implicates bone resorption 
in ectopic calcification, as mice that 
do not express the osteoclast inhibitor 
osteoprotegerin show a combination of 
osteoporosis and extensive vascular cal-
cifi cation.12 Th is paradoxical association 
has also been reported in postmenopau-
sal women with osteoporosis.
Th e exact mechanism by which iband-
ronate prevents vascular calcifi cation in 
rats with adenine-induced chronic renal 
failure is not clear yet. Possibly, the inhi-
bition of bone resorption is the cause of 
this eff ect, as a decrease in bone resorp-
tion goes along with a reduced effl  ux of 
calcium and phosphate from bone into 
the circulatory system, thereby limiting 
their availability for deposition in the 
vasculature, particularly when a normal 
bone formation is maintained. However, 
Price et al.2 did not study (yet) the eff ect 
of ibandronate on bone histology in this 
model, so inhibition of bone resorption 
by bisphosphonate treatment remains to 
be proved, and possible eff ects on bone 
formation and osteoblastic activity will 
need to be checked for. Alternatively, a 
direct eff ect of ibandronate on the ves-
sel wall cannot be precluded, as vascular 
smooth muscle cells can acquire an oste-
oblast-like phenotype in calcifying ves-
sels and when cultured in the presence of 
increased phosphate or calcium levels or 
uremic serum, and bisphosphonates are 
also known to have cell-biological eff ects 
on osteoblastic cells. Moreover, prelimi-
nary results suggest that osteoclast-like 
cells, potential targets for bisphospho-
nate treatment, are sometimes present in 
calcifying vessels of uremic rats (E Neven 
et al., unpublished data). Finally, despite 
that the ibandronate doses used in these 
experiments are unlikely to cause pyro-
phosphate-like eff ects at the arterial wall, 
uremia may be a state of pyrophosphate 
defi ciency, and thus this potential qual-
ity of bisphosphonates should be kept 
in mind.13
Another question to be resolved before 
bisphosphonates can be widely accepted 
as drugs to prevent vascular calcifi ca-
tion in hemodialysis patients is how the 
inhibition of vascular calcification by 
bisphosphonates is influenced by the 
bone turnover rate. Th e eff ect reported by 
Price et al.2 was seen in an experimental 
model with high bone turnover: adenine-
induced uremia causes hyperparathy-
roid bone disease with severely elevated 
parathyroid hormone levels. However, 
further inhibition of the already dramati-
cally impaired bone resorption and/or 
bone formation in low-turnover osteo-
dystrophy might not at all be benefi cial, 
as epidemiological studies reported the 
highest calcifi cation scores in the patients 
with the lowest parathyroid hormone 
values, that is, those with adynamic bone 
disease.1 Experimental evidence point-
ing this out is the fact that treatment of 
uremic low-density lipoprotein receptor 
knockout mice with bone morphogenetic 
protein-7 prevents the development of 
vascular calcifi cation by increasing bone 
turnover in this experimental model of 
adynamic bone disease.14
In summary, Price et al.2 report inter-
esting new eff ects of bisphosphonates in 
experimental uremia-induced chronic 
renal failure, which emphasize once more 
that the mechanisms regulating ectopic 
calcification and bone remodeling are 
intricately intertwined. Th erefore, future 
studies to elucidate the mechanisms of and 
evaluate treatment strategies for uremia-
related vascular calcifi cation will have to 
take into account the complex interplay of 
bone and vessels.
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